Calyxo Raises $32.7 Million in Series C Financing to Support Novel Approach to Treating Kidney Stone
Summary
The companys leadership team has a remarkable track record of recognizing significant unmet physician and patient needs within urology and bringing to market game-changing solutions to meet those needs. We are proud to support this team as it accomplishes its mission to provide a genuine solution for a long-standing medical problem.Newly released results of a nationwide study published in the Journal of Urology indicate that more than five million Americans will pass a kidney stone in 2022, a number that continues with an upward trajectory. According to clinical studies published in Urology and the Journal of Urology, residual fragments left behind are associated with a 20%-44% rate of problems including pain, infection, emergency department visits, hospitalization and need for retreatment, demonstrating the compelling need for innovation in this space.CVAC is a registered trademark of Calyxo, Inc.Calyxo, Inc. is an innovation-driven medical device company focused on improving care for patients with kidney stones by delivering paradigm-shifting solutions that enable urologists to safely, effectively and efficiently achieve unrivaled clinical outcomes. CRG provides growth capital in the form of long-term debt and equity to support innovative, commercial-stage healthcare companies that address large, unmet medical needs. The firm partners with public and private companies to provide flexible financing solutions and world-class support to achieve exceptional growth objectives with minimal dilution.